CME: Role of Fetal Fibronectin (fFN) in the Risk-Assessment for Preterm Birth (PTB)

Role of Fetal Fibronectin (fFN) in the Risk-Assessment for Preterm Birth (PTB)

Role of Fetal Fibronectin (fFN) in the Risk-Assessment for Preterm Birth (PTB)
Dr. Gyamfi-Bannerman discusses fetal fibronectin and how this may have a role in decreasing preterm birth.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    About 30% of preterm labor spontaneously resolves and 50% of patients hospitalized for preterm labor actually give birth at term. Clinicians are left with the task to effectively assess women who are at risk for prenatal delivery in order to prevent preterm labor and reduce perinatal morbidity and mortality. In this activity, clinicians will learn practical strategies combining patient history, fetal fibronectin (fFN) levels, and ultrasonography imaging results to assess patient risks for preterm delivery, in order to provide adequate counseling regarding prenatal care and lifestyle changes.

    To download the algorithms mentioned in this activity, click here.1

    1. McCue, B, Torbenson, VE. Fetal fibronectin: The benefits of a high negative predictive value in management of preterm labor.Contemp Ob Gyn. 2017;62(10)(suppl):1-6

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Cynthia Gyamfi-Bannerman, MD, MSc
    Ellen Jacobson Levine and Eugene Jacobson Professor
    of Women's Health in Obstetrics and Gynecology
    Director, Maternal-Fetal Medicine Fellowship Program
    Co-Director, CUMC Preterm Birth Prevention Center

    Faculty’s disclosure:

    Dr. Gyamfi-Bannerman receives an unrestricted grant for SMFM from AMAG and performs an unrestricted study for Hologic.


    • Ken Brown has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Utilize available algorithm to guide the proper use of fetal fibronectin (fFN) testing, with or without ultrasonography, to assess the risk of preterm birth in symptomatic women over 24 weeks of gestation
    • Interpret the healthcare system benefits of incorporating fFN testing into routine medical practice
  • Target Audience

    This activity is designed to meet the educational needs of Obstetricians, Gynecologists, Maternal Fetal Medicine specialists, Obstetric Hospitalists, CNMs, Labor and Delivery nursing staff, and Women's Health Residents.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Hologic. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Omnia Education newsletters.
Comprehensive women’s health CME.

Better education for a better you.

* Required

We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free